Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

-acute development program. The FDA's recent grant of Fast Track designation and Medtronic's entry into a collaboration agreement to support us in the current trial emphasize the regulatory and commercial interest in cenderitide's potential to address an important unmet medical need for heart failure patients," said Joshua Kazam, Nile's Chief Executive Officer.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, and Nile's ability to obtain FDA approval of cenderitide in the post-acute setting, are forward-looking statements. Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management a
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 The Eastern European ... established medical-device providers as well as new medical-device manufacturers ... while simultaneously looking at ways to reduce the cost ... distributors is one of the effective means to achieve ... distribution market in Eastern European and provides profiles of ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision Resources ... claims data, anemic chronic kidney disease non-dialysis (CKD-ND) ... agent (ESA) medication. In addition, one-year persistency is ... Other key findings from the report ... Analysis of Erythropoiesis Stimulating Agents in Late Stage ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014  Arena ... (PLM) applications, today announced its Fall 2014 release, ... Scribe and Arena DataExtract – ... The newly available products are focused specifically on ... and the aggregation of a complete history of ...
Breaking Medicine Technology:Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
(Date:9/30/2014)... Alan Mozes Health Day Reporter ... Colon cancer patients who are overweight or obese when ... developing a second weight-related cancer, new research suggests. , ... colon cancer recurrence, only the potential for developing other ... colorectal cancer survivors who reported being overweight or obese ...
(Date:9/30/2014)... Next to lung cancer, breast cancer is the leading ... American Cancer Society. That,s why so many medical professionals ... are imperfect at best: only a minority of suspicious ... results in lots of needless worry for women and ... of additional tests, including ultrasounds and biopsies. , ...
(Date:9/30/2014)... CO September 30, 2014 Keystone Symposia will ... the first in its 2014-15 Global Health Series ... the Sheraton Seattle Hotel immediately following the conclusion ... The four-day conference is part of the Keystone Symposia ... Gates Foundation, which has also funded travel awards for ...
(Date:9/30/2014)... A new study of 58 ... impact of stress on metabolism after eating a high-fat meal ... a fast food restaurant, about 930 calories and 60 grams ... minutes every hour for 7 hours, conducting the study twice ... had experienced a stressful event in their lives during the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Integrated ... wellness, is opening another new medical specialty practice through ... IMA Cardiology will be located within the company’s ... Abbud and Dr. Isaac Tawfik of American Heart Center, ... The new practice will offer Integrated Medicine Alliance patients ...
Breaking Medicine News(10 mins):Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:'Virtual breast' could improve cancer detection 2Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... in motor vehicle crashes is closely correlated to the severity ... at the Medical College of Wisconsin in Milwaukee. ... rupture, resulting in bleeding onto the surface of the retina. ... M.D., professors of ophthalmology at the Medical College, is published ...
... for Devastating ... Neurological Disease -, HAILEY, Idaho, June 23 Charles ... on June 17, 2008, for,his support to find a cure for the ... or Parkinson,s disease. Chuck has had PSP for several years,and, despite his ...
... Pacific Corporation, one of,this country,s best kept secrets in ... as part of its current offering to existing and ... review all,financial information up to the second from their ... "We are excited to be able to offer this ...
... Findley Davies, Inc., a human,resources consulting firm, ... Association of Business Communicators (IABC) Cleveland Vision,Awards. For ... HCR,ManorCare, Findley Davies Communication Solutions practice received an,Award ... Davies Communication Solutions practice also received an Award ...
... Insurance,Company ("The Standard"), a subsidiary of StanCorp Financial ... insurance products for employers with as,few as 10 ... line, The,Standard now provides employers with the opportunity ... term disability, life, dental,and vision insurance from a ...
... patients who need little, if any, immune suppression , , ... called HLA-G dimer plays a powerful role in preventing ... Medical College of Georgia researchers say. , They ... mice and are currently studying whether this molecule is ...
Cached Medicine News:Health News:Severe retinal hemorrhaging is linked to severe motor vehicle crashes 2Health News:Advertising Hall of Famer Charles D. Peebler Receives Honor for Work Supporting Cure for Progressive Supernuclear Palsy 2Health News:Oregon Based First Pacific Corporation Launches New E-Tools Program for Dentists 2Health News:Findley Davies Receives IABC Vision Awards 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 2Health News:The Standard Introduces Three Flexible Vision Insurance Plans 3Health News:Immune Molecule Key to Preventing Organ Rejection 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
Medicine Products: